Movers and shakers

The American Cleaning Institute, based in Washington DC, which represents the US cleaning products industry, has appointed four new directors to the board: Liliana De Stefano of the Swiss fragrance and flavour company Firmenich; Jessica McCoy of GOJO Industries, a US manufacturer of hand hygiene and skin care products; Suzanne Carroll of global speciality chemicals company Nouryon; and Eric Stouder of the South African energy and chemicals company Sasol.

Anue Water Technologies, supplier of systems to treat municipal and industrial wastewater, has promoted Gregory Bock to VP general manager, responsible for operations and commercial relations. Bock has over 30 years’ experience in wastewater treatment.

Wolfgang Kintzel is the new CEO of Cellbox Solutions, a spin-off company from the Fraunhofer Research Institution for Marine Biotechnology and Cell Technology in Lübeck, Germany, which focuses on logistic solutions for the global biomedical industry. Company founder Kathrin Adlkofer will support the board as COO.

US oncology-focused biopharmaceutical company CytomX Therapeutics has appointed Alison L. Hannah as senior VP and CMO. Hannah has 30 years’ experience in the development of investigational cancer therapies, having most recently served as a consultant to pharmaceutical and biotechnology companies.

US biopharmaceutical company Everest Medicines, focused on pharmaceutical products that address critical unmet medical needs for patients in China and other parts of Asia, has appointed Kerry Blanchard as CEO. Blanchard, who has clinical expertise with global big pharma and Chinese biotech, will be based in the company’s Shanghai office, and will join the company’s board.

Global pharmaceutical company Gilead Sciences, headquartered in California, US, has appointed Bristol-Myers Squibb’s Michael Quigley as senior VP, research biology. He brings experience in oncology and immuno-oncology biology to the role. In addition, the company has promoted biology head Linda Higgins to senior VP and head of external innovation.

H3 Biomedicine, a US-based precision medicine R&D subsidiary of Japanese pharmaceutical company Eisai, has appointed Antonio Gualberto as CMO. Gualberto joins H3 from precision medicine company Kura Oncology, where he was co-founder and CMO.

US biopharmaceutical company Immunomedics, based in New Jersey, has appointed Loretta Itri as CMO. Itri was most recently at The Medicines Company where she led the development and regulatory approval of a variety of products. She has been working with Immunomedics for the past year overseeing its clinical and regulatory activities.

Chemicals major Merck’s chief information and digital officer Jim Scholefield is moving to US multinational hospitality company Marriott International in the same role. He succeeds Marriott’s CIO Bruce Hoffmeister, who is retiring.

UK independent site management organisation Panthera Biopartners, which has opened its first clinical trial site in Preston, Lancashire, has appointed Joanna Cox as operations director. Cox joins Panthera from Lancashire Care NHS Foundation Trust, where she was the senior research nurse responsible for managing the clinical research team across a range of trials.

PlasticsEurope, the pan-European trade association representing plastics manufacturers, has appointed Virginia Janssens as managing director. Janssens joins from the European Organisation for Packaging and the Environment where she was managing director.

Dutch multinational science-based company Royal DSM, headquartered in Heerlen, has appointed its business group director of resins and functional materials Helen Mets as executive VP materials. She succeeds Dmitri de Vreeze, who is now co- CEO of DSM together with Geraldine Matchett. Mets will become a member of the executive committee of the company.

Sophia Genetics, a health technology company based in Switzerland and the US, has appointed former Foundation Medicine CEO Troy Cox as chairman of the board. He replaces Antoine Duchateau, who will continue as a board member.

Spark Therapeutics co-founder and R&D head Kathy High has left the US gene therapy company in the wake of its takeover by Swiss healthcare major Roche.

US oncology company Turning Point Therapeutics, based in San Diego, CA, has appointed Siegfried Reich as executive VP and CSO. Reich has over 25 years’ pharmaceutical and biotech experience developing drug candidates, including for HIV and kidney cancer. He was previously co-founder of Effector Therapeutics, an early-stage company focused on small molecule cancer therapeutics.